Literature DB >> 25270900

Targeted temperature management at 33°C versus 36°C and impact on systemic vascular resistance and myocardial function after out-of-hospital cardiac arrest: a sub-study of the Target Temperature Management Trial.

John Bro-Jeppesen1, Christian Hassager2, Michael Wanscher2, Morten Østergaard2, Niklas Nielsen2, David Erlinge2, Hans Friberg2, Lars Køber2, Jesper Kjaergaard2.   

Abstract

BACKGROUND: Cardiovascular dysfunction is common after out-of-hospital cardiac arrest as part of the postcardiac arrest syndrome, and hypothermia may pose additional impact on hemodynamics. The aim was to investigate systemic vascular resistance index (SVRI), cardiac index, and myocardial performance at a targeted temperature management of 33°C (TTM33) versus 36°C (TTM36). METHODS AND
RESULTS: Single-center substudy of 171 patients included in the Target Temperature Management Trial (TTM Trial) randomly assigned to TTM33 or TTM36 for 24 hours after out-of-hospital cardiac arrest. Mean arterial pressure ≥65 mm Hg and central venous pressure of 10 to 15 mm Hg were hemodynamic treatment goals. Hemodynamic evaluation was performed by serial right heart catheterization and transthoracic echocardiography. Primary end point was SVRI after 24 hours of cooling and secondary end points included mean SVRI, cardiac index, systolic function, and lactate levels. The TTM33 group had a significant increase in SVRI compared with TTM36 (2595; 95% confidence interval, 2422-2767) versus 1960 (95% confidence interval, 1787-2134) dynes m(2)/s per cm(5); P<0.0001, respectively) after 24 hours of cooling with an overall difference of 556 dynes m(2)/s per cm(5) (P(group) <0.0001). TTM33 was associated with decreased cardiac index (-0.4 L/min per m(2); P(group) <0.0001), decreased heart rate (P(group)=0.01), and stroke volume index (P(group)=0.004) compared with TTM36. Left ventricular ejection fraction (P=0.39) and peak systolic myocardial velocity (P=0.62) did not differ between TTM groups. Lactate levels were significantly higher in the TTM33 group (P=0.0008).
CONCLUSIONS: Targeted temperature management at 33°C with target mean arterial pressure ≥65 mm Hg is associated with increased SVRI and lower cardiac index because of lower heart rate with unaffected left ventricular systolic function compared with 36°C. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01020916.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  heart arrest; hemodynamics; hypothermia; myocardial contraction

Mesh:

Year:  2014        PMID: 25270900     DOI: 10.1161/CIRCINTERVENTIONS.114.001556

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  17 in total

1.  Comparison of non-invasive vs invasive blood pressure measurement in neonates undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy.

Authors:  J Zhou; O Elkhateeb; K-S Lee
Journal:  J Perinatol       Date:  2016-01-07       Impact factor: 2.521

Review 2.  Advances in clinical studies of cardiopulmonary resuscitation.

Authors:  Shou-Quan Chen
Journal:  World J Emerg Med       Date:  2015

3.  Pulmonary Arterial Compliance in Acute Respiratory Distress Syndrome: Clinical Determinants and Association With Outcome From the Fluid and Catheter Treatment Trial Cohort.

Authors:  Thomas S Metkus; Emmanouil Tampakakis; Christopher J Mullin; Brian A Houston; Todd M Kolb; Stephen C Mathai; Rachel Damico; Bradley A Maron; Paul M Hassoun; Roy G Brower; Ryan J Tedford
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

4.  Myocardial dysfunction after out-of-hospital cardiac arrest: predictors and prognostic implications.

Authors:  Yuan Yao; Nicholas James Johnson; Sarah Muirhead Perman; Vimal Ramjee; Anne Victoria Grossestreuer; David Foster Gaieski
Journal:  Intern Emerg Med       Date:  2017-10-05       Impact factor: 3.397

5.  Validation of the CREST score for predicting circulatory-aetiology death in out-of-hospital cardiac arrest without STEMI.

Authors:  Timothy N Jones; Matthew Kelham; Krishnaraj S Rathod; Charles J Knight; Alastair Proudfoot; Ajay K Jain; Andrew Wragg; Muhiddin Ozkor; Paul Rees; Oliver Guttmann; Andreas Baumbach; Anthony Mathur; Daniel A Jones
Journal:  Am J Cardiovasc Dis       Date:  2021-12-15

Review 6.  Myocardial Dysfunction and Shock after Cardiac Arrest.

Authors:  Jacob C Jentzer; Meshe D Chonde; Cameron Dezfulian
Journal:  Biomed Res Int       Date:  2015-09-02       Impact factor: 3.411

7.  Transitions Between Circulatory States After Out-of-Hospital Cardiac Arrest: Protocol for an Observational, Prospective Cohort Study.

Authors:  Halvor Langeland; Daniel Bergum; Magnus Løberg; Knut Bjørnstad; Jan Kristian Damås; Tom Eirik Mollnes; Nils-Kristian Skjærvold; Pål Klepstad
Journal:  JMIR Res Protoc       Date:  2018-01-19

8.  Renal function after out-of-hospital cardiac arrest; the influence of temperature management and coronary angiography, a post hoc study of the target temperature management trial.

Authors:  Malin Rundgren; Susann Ullén; Matt P G Morgan; Guy Glover; Julius Cranshaw; Nawaf Al-Subaie; Andrew Walden; Michael Joannidis; Marlies Ostermann; Josef Dankiewicz; Niklas Nielsen; Matthew P Wise
Journal:  Crit Care       Date:  2019-05-08       Impact factor: 9.097

9.  Mean arterial pressure is associated with the neurological function in patients who survived after cardiopulmonary resuscitation: A retrospective cohort study.

Authors:  Hai-Bo Ai; En-Li Jiang; Ji-Hua Yu; Lin-Bo Xiong; Qi Yang; Qi-Zu Jin; Wen-Yan Gong; Shuai Chen; Hong Zhang
Journal:  Clin Cardiol       Date:  2020-08-01       Impact factor: 2.882

10.  Continuous Neuromuscular Blockade Following Successful Resuscitation From Cardiac Arrest: A Randomized Trial.

Authors:  Ari Moskowitz; Lars W Andersen; Jon C Rittenberger; Robert Swor; Raghu R Seethala; Michael C Kurz; Katherine M Berg; Maureen Chase; Michael N Cocchi; Anne V Grossestreuer; Xiaowen Liu; Mathias J Holmberg; Clifton W Callaway; Michael W Donnino
Journal:  J Am Heart Assoc       Date:  2020-08-27       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.